The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines

The current COVID-19 pandemic is a massive source of global disruption, having led so far to two hundred and fifty million COVID-19 cases and almost five million deaths worldwide. It was recognized in the beginning that only an effective vaccine could lead to a way out of the pandemic, and therefore...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pedro Morais, Hironori Adachi, Yi-Tao Yu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COVID-19 SARS-CoV-2 mRNA vaccines RNA modification pseudouridine Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/fb6a4596b2f94b4cbe9d7cc377d7a8b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb6a4596b2f94b4cbe9d7cc377d7a8b6
record_format	dspace
spelling	oai:doaj.org-article:fb6a4596b2f94b4cbe9d7cc377d7a8b62021-11-04T07:04:44ZThe Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines2296-634X10.3389/fcell.2021.789427https://doaj.org/article/fb6a4596b2f94b4cbe9d7cc377d7a8b62021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcell.2021.789427/fullhttps://doaj.org/toc/2296-634XThe current COVID-19 pandemic is a massive source of global disruption, having led so far to two hundred and fifty million COVID-19 cases and almost five million deaths worldwide. It was recognized in the beginning that only an effective vaccine could lead to a way out of the pandemic, and therefore the race for the COVID-19 vaccine started immediately, boosted by the availability of the viral sequence data. Two novel vaccine platforms, based on mRNA technology, were developed in 2020 by Pfizer-BioNTech and Moderna Therapeutics (comirnaty® and spikevax®, respectively), and were the first ones presenting efficacies higher than 90%. Both consisted of N1-methyl-pseudouridine-modified mRNA encoding the SARS-COVID-19 Spike protein and were delivered with a lipid nanoparticle (LNP) formulation. Because the delivery problem of ribonucleic acids had been known for decades, the success of LNPs was quickly hailed by many as the unsung hero of COVID-19 mRNA vaccines. However, the clinical trial efficacy results of the Curevac mRNA vaccine (CVnCoV) suggested that the delivery system was not the only key to the success. CVnCoV consisted of an unmodified mRNA (encoding the same spike protein as Moderna and Pfizer-BioNTech’s mRNA vaccines) and was formulated with the same LNP as Pfizer-BioNTech’s vaccine (Acuitas ALC-0315). However, its efficacy was only 48%. This striking difference in efficacy could be attributed to the presence of a critical RNA modification (N1-methyl-pseudouridine) in the Pfizer-BioNTech and Moderna’s mRNA vaccines (but not in CVnCoV). Here we highlight the features of N1-methyl-pseudouridine and its contributions to mRNA vaccines.Pedro MoraisHironori AdachiYi-Tao YuFrontiers Media S.A.articleCOVID-19SARS-CoV-2mRNAvaccinesRNA modificationpseudouridineBiology (General)QH301-705.5ENFrontiers in Cell and Developmental Biology, Vol 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 SARS-CoV-2 mRNA vaccines RNA modification pseudouridine Biology (General) QH301-705.5
spellingShingle	COVID-19 SARS-CoV-2 mRNA vaccines RNA modification pseudouridine Biology (General) QH301-705.5 Pedro Morais Hironori Adachi Yi-Tao Yu The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
description	The current COVID-19 pandemic is a massive source of global disruption, having led so far to two hundred and fifty million COVID-19 cases and almost five million deaths worldwide. It was recognized in the beginning that only an effective vaccine could lead to a way out of the pandemic, and therefore the race for the COVID-19 vaccine started immediately, boosted by the availability of the viral sequence data. Two novel vaccine platforms, based on mRNA technology, were developed in 2020 by Pfizer-BioNTech and Moderna Therapeutics (comirnaty® and spikevax®, respectively), and were the first ones presenting efficacies higher than 90%. Both consisted of N1-methyl-pseudouridine-modified mRNA encoding the SARS-COVID-19 Spike protein and were delivered with a lipid nanoparticle (LNP) formulation. Because the delivery problem of ribonucleic acids had been known for decades, the success of LNPs was quickly hailed by many as the unsung hero of COVID-19 mRNA vaccines. However, the clinical trial efficacy results of the Curevac mRNA vaccine (CVnCoV) suggested that the delivery system was not the only key to the success. CVnCoV consisted of an unmodified mRNA (encoding the same spike protein as Moderna and Pfizer-BioNTech’s mRNA vaccines) and was formulated with the same LNP as Pfizer-BioNTech’s vaccine (Acuitas ALC-0315). However, its efficacy was only 48%. This striking difference in efficacy could be attributed to the presence of a critical RNA modification (N1-methyl-pseudouridine) in the Pfizer-BioNTech and Moderna’s mRNA vaccines (but not in CVnCoV). Here we highlight the features of N1-methyl-pseudouridine and its contributions to mRNA vaccines.
format	article
author	Pedro Morais Hironori Adachi Yi-Tao Yu
author_facet	Pedro Morais Hironori Adachi Yi-Tao Yu
author_sort	Pedro Morais
title	The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
title_short	The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
title_full	The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
title_fullStr	The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
title_full_unstemmed	The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
title_sort	critical contribution of pseudouridine to mrna covid-19 vaccines
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/fb6a4596b2f94b4cbe9d7cc377d7a8b6
work_keys_str_mv	AT pedromorais thecriticalcontributionofpseudouridinetomrnacovid19vaccines AT hironoriadachi thecriticalcontributionofpseudouridinetomrnacovid19vaccines AT yitaoyu thecriticalcontributionofpseudouridinetomrnacovid19vaccines AT pedromorais criticalcontributionofpseudouridinetomrnacovid19vaccines AT hironoriadachi criticalcontributionofpseudouridinetomrnacovid19vaccines AT yitaoyu criticalcontributionofpseudouridinetomrnacovid19vaccines
_version_	1718445059331850240

The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines

Ejemplares similares